



April 16, 2014

The Dy. General Manager  
Dept. of Corporate Affairs  
The Bombay Stock Exchange Ltd,  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai: 400001

Dear Sir,

We are enclosing herewith a press release informing "Glenmark Generics receives final ANDA approval for Eszopiclone Tablets" for your information and record.

Thanking you.

Yours faithfully,  
For Glenmark Pharmaceuticals Ltd.

**Sanjay Kumar Chowdhary**  
Company Secretary & Compliance Officer

Tel: 4018 9999 / 4018 9879  
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: as above

Press Release

For Immediate Release

## **Glenmark Generics receives final ANDA approval for Eszopiclone Tablets**

**April 16, 2014:** Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Eszopiclone Tablets. Glenmark will commence distribution of the product immediately.

Eszopiclone Tablets are Glenmark's generic version of Sunovion's Lunesta®. Eszopiclone is indicated for the treatment of insomnia. The approval is for the 1mg, 2mg and 3mg tablets. For the 12 month period ending December 2013, Lunesta® garnered annual sales of USD 824 Million according to IMS Health.

Glenmark's current portfolio consists of 91 products authorized for distribution in the U.S. marketplace and 63 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

### **About Glenmark Generics Limited**

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

### **For further information, please contact:**

Jason D'Souza / Rajdeep Barooah

Glenmark, Mumbai, India Tel: [+91 22] 40189919/984

Email: [corpcomm@glenmarkpharma.com](mailto:corpcomm@glenmarkpharma.com)